Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Chemoprevention therapy is the use of certain drugs to try to prevent the development of
cancer. The use of celecoxib has been approved for use in reducing the number of adenomatous
colorectal polyps in familial adenomatous polyposis (FAP). It is not known whether there is a
clinical benefit from a reduction in the number of colorectal polyps in FAP patients. The use
of celecoxib may be an effective way to prevent the development of sporadic adenomatous
polyps, precursors of colorectal cancer. This randomized phase III trial is studying
celecoxib to see how well it works compared to a placebo in preventing the development of
adenomatous colorectal polyps in patients who have had at least one polyp removed.